Filing Flows › Aquestive Therapeutics (AQST) › Co-development and research fees revenue
Aquestive Therapeutics (AQST) Co-development and research fees revenue by quarter
Aquestive Therapeutics' Co-development and research fees revenue was $74K in Q3 2026 (third quarter 2026), -87% from Q2 2026. Over the last 6 quarters it ranged from $74K (Q3 2026) to $582K (Q2 2026).
| Quarter | Co-development and research fees revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $74K | -87% | -75% |
| Q2 2026 | $582K | +126% | — |
| Q1 2026 | $258K | +43% | -38% |
| Q4 2025 | $181K | -40% | — |
| Q3 2025 | $302K | -28% | — |
| Q1 2025 | $418K | — | — |
Q3 2026 at a glance
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aquestive Therapeutics' Co-development and research fees revenue?
Aquestive Therapeutics' Co-development and research fees revenue was $74K in Q3 2026 (third quarter 2026), -87% from Q2 2026.
How has Aquestive Therapeutics' Co-development and research fees revenue changed?
Over the last 6 quarters it ranged from $74K (Q3 2026) to $582K (Q2 2026).
Q3 2026 results → · How Aquestive Therapeutics makes money →